Sorafenib Did Not Improve RFS in mRCC After Radical Resection

John SchieszerJun 5, 2018In the Italian RESORT trial, sorafenib did not affect recurrence-free survival in patients with mRCC following radical resection of metastases.

Source: CancerNetwork - June 5, 2018 Category: Cancer & Oncology Authors: A Source Type: news